Ann: RC220 GLP Non-clinical Toxicology Program Successful, page-17

Yes it is certainly a great feeling to have reached this stage in the re-development of bisantrene. Solving the problem that led to bisantrene being dropped by Lederle (solubility) really is a major step forward. I know some investors and doctors think chemotherapy is old hat and boring, but for the majority of patients it is standard of care. We need to make sure that if we give chemotherapy that the patient is not left permanently damaged - there is no point curing someone of cancer if you end up giving them heart failure. Onwards and upwards.